Rational Modifications to CAR Antigen Binding Domain Improve Sensitivity to Low-Density Target Antigens

C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract

Chimeric antigen receptor (CAR) T cells have demonstrated significant success in treating relapsed or treatment-refractory hematologic malignancies in the clinic, inducing remissions in 70-90% of pediatric patients with B-lineage acute lymphoblastic leukemia (B-ALL). Unfortunately, up to half of patients will eventually relapse, often due to poor CAR T cell expansion/persistence or modulation of the target antigen by tumor cells. One mechanism of antigen modulation is a decrease in surface expression of the CAR-targeted antigen, as seen in clinical trials with CAR T cells targeting the CD22 antigen in B-ALL, as well as in trials targeting solid tumors. Based on clinical data from our anti-CD22 CAR trial, we believe that sensitivity to low expression of the CD22 target antigen is important for efficacy of CARs targeting this antigen, and have shown in xengraft models that CAR T cells are less effective in responding to leukemia with low expression of the target antigen (CD22Lo).  Antigen downregulation thus represents a major mechanism of resistance to CAR T cell therapy and an area for improvement. Recent work from our lab and others have implicated the CAR antigen binding domain as an important factor in the efficacy of CARs responding to the CD22 target antigen. We have set out to characterize the effects of multiple modifications to the antigen binding domain on CAR responses to CD22Lo leukemia as a means to enhance overall CD22 CAR response rates. Collectively, these investigations will deepen our understanding of the factors important to designing CARs which are capable of targeting tumors with weakly-expressed antigens.

Learning Objectives:

1. Describe the impact of leukemic target antigen density on CAR T cells. 

2. Identify a way in which the CAR antigen binding domain can be modified. 

3. Identify one T cell function which is impacted by leukemic target antigen density. 


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
MAY 11, 2021 10:00 AM PDT
C.E. CREDITS
MAY 11, 2021 10:00 AM PDT
Date: May 11, 2021 Time: 10:00zm PDT Your samples are some of the most valuable assets in the laboratory. After spending countless hours on extraction and preparation, your conclusions could...
APR 21, 2021 10:00 AM PDT
C.E. CREDITS
APR 21, 2021 10:00 AM PDT
Date: April 21, 2021 Time: 10:00am (PDT), 1:00pm (EDT) Serological testing for SARS-CoV-2 has been steadily adopted into clinical practice over the course of this pandemic. In this webinar,...
FEB 24, 2021 10:00 AM PST
C.E. CREDITS
FEB 24, 2021 10:00 AM PST
DATE: February 24, 2021 TIME: 10am PST Automated lab instruments such as liquid handlers and cell sorters are increasingly common in all types of laboratories, driving fast results for labor...
JUN 09, 2021 7:00 AM PDT
C.E. CREDITS
JUN 09, 2021 7:00 AM PDT
Date: June 9, 2021 Time: 09 June 2021, 7am PDT, 10am EDT, 4pm CEST cells with dramatic implications on the validity of past cell culture related research. The fact that at least 509 cell lin...
JUN 03, 2021 12:00 PM CST
JUN 03, 2021 12:00 PM CST
DATE: June 3, 2021 TIME: 12:00pm SGT This webinar is a virtual event that focuses on utilizing the Gibco CTS Rotea System for Cell and Gene Therapy...
Loading Comments...
Show Resources